AgeX Therapeutics Inc

AGE

$

Closing

1D

YTD

AGE

Market cap

$

52 week high

$

52 week low

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

-

52 week high

$

52 week low

$

Div. Yield

%

EPS Annual Growth

0.00

Company Profile

AgeX Therapeutics, Inc. is a biotechnology company. The Company is focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The Company’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows utilizing telomerase-expressing regenerative pluripotent stem cells (PSCs) for the manufacture of cell-based therapies. Its cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy comprised of young regenerative vascular-forming cells. AGEX-VASC1 may restore vascular support in aged ischemic tissues such as in peripheral vascular disease and ischemic heart disease.